rethinkTHC Search
Menu
Study breakdown

Review maps drug interactions between antiepileptic medications and cannabinoids

ReviewModerate evidence
The takeaway

Cannabinoid-AED combinations can enhance seizure protection but also increase side effects, with CBD clinical trials showing 14-35% dropout rates and common side effects of diarrhea, somnolence, and poor appetite.

Epileptologists, pharmacists managing AED regimens, and patients on CBD plus AEDs.

14-35% retention rate for CBD add-on

What the researchers found

In animal models, WIN 55,212-2 (CB1/CB2 agonist) potentiated anticonvulsant activity of various AEDs but caused profound neurotoxicity when combined with conventional AEDs. ACEA (selective CB1 agonist) enhanced phenobarbital and levetiracetam without adverse effects or pharmacokinetic interactions. Clinical CBD add-on therapy reduced seizure frequency with retention rates of 14-24% at 12 weeks to 1 year, reaching 35% at 2 years.

Why it matters

Most epilepsy patients on CBD are taking multiple other medications. Understanding which combinations are safe and effective is critical for clinical practice, especially as CBD use in epilepsy grows rapidly.

The numbers in context

Clinical CBD retention rate: 14-24% (12 weeks to 1 year), 35% at 2 years. Most common AEs: diarrhea, somnolence, poor appetite. ACEA enhanced phenobarbital and levetiracetam without pharmacokinetic interactions in mice.

How the study worked

Literature review of PubMed through December 2018, covering both experimental (animal model) and clinical data on AED-cannabinoid interactions.

What this study cannot tell us

Animal interaction data may not translate directly to humans. Clinical retention rates reflect a mix of efficacy and tolerability. Limited pharmacokinetic interaction data in humans.

How to read the evidence

Moderate: comprehensive review of both experimental and clinical data.

When this study was published

Published in 2019.

The bigger picture

The distinction between CB1/CB2 non-selective agonists (toxic combinations) and selective CB1 agonists (clean combinations with certain AEDs) has practical implications for developing safer cannabinoid-AED combinations.

Questions still open

  • Which specific AED-CBD combinations have the best efficacy-safety profile? Can selective CB1 agonists be developed for clinical use in epilepsy?

Common questions

Does CBD interact with seizure medications?
Yes, CBD can enhance the effects of certain AEDs. Clinical trials show common interactions include increased somnolence and diarrhea, with dropout rates of 14-35% over time.
Are some cannabinoid-AED combinations safer?
Animal studies suggest selective CB1 agonists (like ACEA) can enhance certain AEDs without the neurotoxic effects seen with non-selective cannabinoid agonists.

Read the original research

Drug-drug interactions between antiepileptics and cannabinoids.

Expert opinion on drug metabolism & toxicology, 15(5), 407-415

Citation

Miziak, Barbara; Walczak, Aleksandra; Szponar, Jarosław; Pluta, Ryszard; Czuczwar, Stanisław J. (2019). Drug-drug interactions between antiepileptics and cannabinoids.. Expert opinion on drug metabolism & toxicology, 15(5), 407-415. https://doi.org/10.1080/17425255.2019.1605355

Explore the wider topic